Screening | Baseline | |||
---|---|---|---|---|
Evaluations/interventions | Week 0 | Week 0 | Week 5 | Week 10 |
Inclusion and exclusion criteria | X | X | ||
Current use of medication/supplements | X | X | X | X |
Informed consents | X | |||
Randomisation | X | |||
Treatment | ||||
Treatment distribution | X | |||
Medication count | X | X | ||
ADHD-RS | X | X | X | |
SEQ | X | X | ||
PCQ | X | X | X | |
FFQ | X | X | ||
Blood and urine collection | X | X | ||
Faeces collection | X | X | ||
GSH analysis | X | X | ||
Lipid-soluble antioxidants analysis | X | X | ||
Antioxidant enzyme activity | X | X | ||
Genetics analysis | X | X | ||
MDA analysis | X | X | ||
8-OHdG analysis | X | X | ||
Cytokine analysis | X | X | ||
Antibody analysis | X | X | ||
PBMC count and reactivity analysis | X | X | ||
Microbial composition analysis | X | X | ||
Catecholamine analysis | X | X | ||
NPY analysis | X | X | ||
Zinc analysis | X | X |